REGN Earnings Prediction
The chart below shows how REGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, REGN sees a -0.34% change in stock price 10 days leading up to the earnings, and a -0.02% change 10 days following the report. On the earnings day itself, the stock moves by +0.14%. This data can give you a slight idea of what to expect for the next quarter's release.
REGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
3.72B
10.65%
4.89%
Gross Margin
86.80%
-0.25%
0.39%
Operating Margin
33.21%
-7.78%
6.31%
Net Margin
36.03%
20.22%
-10.77%
EPS
11.54
29.81%
-7.01%
No Data Available
REGN Earnings Analysis
Regeneron Pharmaceuticals Inc Corporation (REGN.O) Earnings Conference Call
Positive
Revenue Increase Q3 2024: 1. Strong Revenue Growth: Regeneron reported total revenues of $3.72 billion for Q3 2024, reflecting an 11% year-over-year increase, primarily driven by higher collaboration revenues and product sales.
Dupixent Revenue Milestone: 2. Dupixent Milestone: Dupixent achieved global revenues of $3.8 billion in Q3 2024, marking a 24% increase on a constant currency basis, with over 1 million patients currently on treatment across seven approved indications.
EYLEA HD Sales Growth: 3. EYLEA HD Performance: EYLEA HD generated $392 million in net sales during its first full quarter, representing a 29% sequential growth, and combined EYLEA and EYLEA HD captured approximately 44% of the total anti-VEGF market share.
Collaboration Profit Growth: 4. Increased Collaboration Profits: Regeneron's share of profits from its collaboration with Sanofi grew 26% year-over-year, reaching $1.3 billion in Q3 2024, driven by volume growth for Dupixent and improving collaboration margins.
Strong Free Cash Flow: 5. Robust Free Cash Flow: Regeneron generated approximately $2.6 billion in free cash flow through the first nine months of 2024, ending the quarter with cash and marketable securities less debt of approximately $15.6 billion.
Negative
Gross Margin Decline: 1. Declining Gross Margin: Regeneron's gross margin on net product sales decreased to 89% in Q3 2024, down from 90% in the prior year, primarily due to higher start-up costs for their fill/finish manufacturing facility.
R&D Expense Increase: 2. Increased R&D Expenses: Research and development expenses rose to $1.1 billion in Q3 2024, reflecting ongoing investments in the pipeline, which may strain future profitability.
Rising SG&A Expenses: 3. Higher SG&A Costs: Selling, general, and administrative expenses increased by 15% year-over-year to $613 million in Q3 2024, indicating rising operational costs that could impact margins.
Inventory's Future Sales Effect: 4. Inventory Impact on Future Sales: EYLEA HD's net sales were positively impacted by approximately $40 million due to higher wholesaler inventory levels, but this is expected to negatively affect Q4 2024 sales as inventory is absorbed.
Development Balance Decline: 5. Reduced Sanofi Development Balance: The Sanofi development balance decreased by approximately $200 million from the end of Q2 2024, indicating potential challenges in collaboration profitability moving forward.
REGN FAQs
How does REGN typically perform around its earnings report dates?
Is Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
REGN Earning Call Sentiment
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
REGN.O
1.32%Positive
The earnings call highlights strong financial performance, especially with significant revenue growth from Dupixent and EYLEA, and substantial free cash flow generation. The commitment to shareholder returns through share repurchases is positive. Despite some concerns about wholesaler inventory levels and competitive pressure from biosimilars, management's optimism about product differentiation and upcoming launches supports a positive outlook. The Q&A section reveals confidence in future growth, though some responses were vague. Overall, the sentiment leans positive due to strong financials and strategic initiatives, predicting a stock price increase of 2% to 8% over the next two weeks.